Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds

Cancer

Volumn 78, Issue 9, 1996, Pages 1996-2003

  Blank, Robert D ^a,b,c   Sklar, Charles A ^c   Dimich, Alexandra B ^a   LaQuaglia, Michael P ^a   Brennan, Murray F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

calcitonin; hyperparathyroidism; neurocristopathy; pheochromocytoma; thyroid neoplasms; tyrosine kinase

Indexed keywords

CALCITONIN; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE; HIRSCHSPRUNG DISEASE; HUMAN; HYPERPARATHYROIDISM; MALIGNANT TRANSFORMATION; MULTIPLE ENDOCRINE NEOPLASIA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID TUMOR;

ADULT; CHILD; FAMILY; FEMALE; HIRSCHSPRUNG DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; ONCOGENE PROTEINS; PEDIGREE; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0029823617     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961101)78:9<1996::AID-CNCR22>3.0.CO;2-S     Document Type: Article

References (47)

1. Wolfe HJ, Melvin KEW, Cervi-Skinner SJ, Al Saadi AA, Juliar JF, Jackson CE, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-41.
2. Carney JA, Go VLW, Sizemore GW, Hayles AB. Alimentarytract ganglioneuromatosis: a major component of the syndrome of multiple endocrine neoplasia, type 2b. N Engl J Med 1976;295:1287-91.
3. Carney JA, Hayles AB. Alimentary tract manifestations of multiple endocrine neoplasia, type 2b. Mayo Clin Proc 1977; 52:543-8.
4. Bergholm U, Adami H-O, Bergstrom R, Akerstrom G, Group SMS. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 1989;63:1196-204.
5. Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH, Jr. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg 1980; 115:142-8.
6. Simpson WJ, Carruthers JS, Malkin D. Results of a screening program from C-cell disease (medullary thyroid cancer and C-cell hyperplasia). Cancer 1990;65:1570-6.
7. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994;91:1579-83.
8. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
9. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-41.
10. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367:375-6.
11. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458-60.
12. Ceccherini I, Hofstra R, Luo Y, Stulp RP, Barone V, Stelwagen T, et al. DNA Polymorphisms and conditions for SSCP analysis of the 20 exons of the RET proto-oncogene. Oncogene 1994;9:3025-9.
13. Chi DD, Toshima K, Donis-Keller H, Wells SA, Jr. Predictive testing for multiple endocrine neoplasia type 2A (MEN 2A) based on the detection of mutations in the RET protooncogene. Surgery 1994;116:124-33.
14. Marsh DJ, Robinson BG, Andrew S, Richardson A-L, Pojer R, Schnitzler M, et al. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994;23:477-9.
15. McMahon R, Mulligan LM, Healey CS, Payne SJ, Ponder M, Ferguson-Smith MA, et al. Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families. Hum Mol Genet 1994;3:643-6.
16. Wells SAJ, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-50.
17. Xue F, Yu H, Maurer LH, Memoli VA, Nutile-McMenemy N, Schuster MK, et al. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests. Hum Mol Genet 1994;3:635-8.
18. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994;367:378-80.
19. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994;367:377-8.
20. van Heyningen V. One gene-four syndromes. Nature 1994; 367:319-20.
21. Decker RA. Expression of papillary thyroid carcinoma in multiple endocrine neoplasia type 2A. Surgery 1993;114: 1059-63.
22. Mulligan LM, Ponder BAJ. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995;80:1989-95.
23. Blank RD, Sklar CA, Martin ML. Denaturing gradient gel electrophoresis to diagnose multiple endocrine neoplasia type 2. Clin Chem 1996;42:598-603.
24. Sheffield VC, Cox DR, Lerman LS, Myers RM. Attachment of a 40-base-pair clamp (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci USA 1989;86:232-6.
25. Rossel M, Schuffenecker I, Schlumberger M, Bonnardel C, Modigliani E, Gardet P, et al. Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet 1995;95:403-6.
26. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet 1994;3:1259-62.
27. Kempter B, Ritter MM. Unexpected high calcitonin concentrations after pentagastrin stimulation. Clin Chem 1991; 37:473-4.
28. Landsvater RM, Rombouts AGM, te Meerman GJ, Jansen Schillhorn-van Veen JM, Berends MJH, Geerdink RA, et al. The clinical implications of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of an MEN2A kindred. Am J Hum Genet 1993;52:335-42.
29. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994; 3:2163-7.
30. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the RET proto-oncogene encoding a tyrosine kinase with two potential transmem-brane domains. Oncogene 1988;3:571-8.
31. Takahashi M, Buma Y, Hiai H. Isolation of RET proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 1989;4:805-6.
32. Takiguchi-Shirahama S, Koyama K, Miyauchi A, Waksugi T, Oishi S, Takami H, et al. Germline mutations of the RET proto-oncogene in eight Japanese patients with multiple endocrine neoplasia type 2A (MEN2A). Hum Genet 1995; 95:187-90.
33. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, et al. RET proto-oncogene mutations in French MEN 2A and FMTC Families. Hum Mol Genet 1994;3:1939-43.
34. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-13.
35. Mulligan LM, Eng C, Healey CS, Ponder MA, Feldman GL, Li P, et al. A de novo mutation of the RET proto-oncogene in a patient with MEN 2A. Hum Mol Genet 1994;3:1007-8.
36. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in Human thyroid papillary carcinomas. Cell 1990;60:557-63.
37. Pierotti MA, Santoro M, Jenkins RB, Sozzi G, Bongarzone I, Grieco M, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA 1992;89:1616-20.
38. Bongarzone I, Monzini N, Borrello MG, Carcano C, Ferraresi G, Arighi E, et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of RET tyrosine kinase and the regulatory subunit RIa of cyclic AMP-dependent protein kinase A. Mol Cell Biol 1993;13:358-66.
39. Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, et al. Frequent activation of RET protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 1994;54:2979-85.
40. Jhiang SM, Mazzaferri EL. The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 1994;123:331-7.
41. Lanzi C, Borrello MG, Bongarzone I, Migliazza A, Fusco A, Grieco M, et al. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. Oncogene 1992;7:2189-94.
42. Nelkin BD, Nakamura Y, White RW, de Bustros AC, Herman J, Wells SA Jr., et al. Low incidence of loss of chromosome 10 in sporadic and hereditary Human medullary thyroid carcinoma. Cancer Res 1989;49:4114-9.
43. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. Nature 1994;367:380-3.
44. Attie T, Pelet A, Sarda P, Eng C, Edery P, Mulligan LM, et al. A 7 bp deletion of the RET proto-oncogene in familial Hirschsprung's disease. Hum Mol Genet 1994;3:1439-40.
45. Luo Y, Ceccherini I, Pasini B, Matera I, Bicocchi MP, Barone V, et al. Close linkage with the RET proto-oncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. Hum Mol Genet 1993;2:1803-8.
46. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the RET proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613-9.
47. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-3.